Cabozantinib-d6

CAT: 0804-HY-13016S-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13016S-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Cabozantinib-d6 is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].
CAS Number
[1802168-46-2]
Product Name Alternative
XL184-d6; BMS-907351-d6
UNSPSC
12352005
Target
Apoptosis; c-Kit; c-Met/HGFR; FLT3; TAM Receptor; VEGFR
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
98.14
Solubility
DMSO : 25mg/mL (ultrasonic) |H2O : 1mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
C(NC1=CC=C(OC=2C3=C(C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C3)N=CC2)C=C1)(=O)C4(C(NC5=CC=C(F)C=C5)=O)CC4
Molecular Formula
C28H18D6FN3O5
Molecular Weight
507.54
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71 (14), 4758-4768.|[3]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10 (12), 2298-2308.|[4]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16 (11) :2387-2398.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
Axl

Related Products

CatalogName
HY-13016-01Cabozantinib
HY-13016ACabozantinib (hydrochloride)
HY-13016R-01Cabozantinib (Standard)
HY-13016S1-01Cabozantinib-d4
HY-Z2199-01Cabozantinib impurity 1
HY-Z1053-01Cabozantinib impurity 8
HY-12044-01Cabozantinib (S-malate)
HY-Z2093-01Cabozantinib impurity 7
HY-Z1053RCabozantinib impurity 8 (Standard)
HY-Z2199RCabozantinib impurity 1 (Standard)

Alternative Products

CatalogName
RM-C022654-01Cabozantinib-D6
MBS3606163-01Cabozantinib
M28470-01Cabozantinib hydrochloride
RM-C291000-01Cabozantinib Malate
MBS8506340-01XL184 (Cabozantinib)
abx182391-01Cabozantinib, XL184
RM-C022601-01Cabozantinib Impurity A
S1119-5mgCabozantinib (XL184)

Popular Products